IDH1 inhibitors show strong efficacy and tolerability in IDH1-mutated AML and MDS, with some patients achieving long-term ...

Inhibrx Biosciences is vying for approval of its targeted therapy, ozekibart, in chondrosarcoma. This follows the positive ...

Servier looks like it could bring a second IDH inhibitor from its 2021 takeover of Agios’ oncology business to market, after reporting positive results in a phase 3 brain cancer trial. The drug ...

This article describes two pediatric SM with AML1::ETO+ AML patients induced by novel KIT exon11 mutations not previously documented in medical literature. Both patients underwent allogeneic ...

AML develops quickly, with symptoms like bone pain and shortness of breath, while CML progresses slowly and can start with weight loss and night sweats. AML is more common in both children and adults, ...

Acute myeloid leukemia (AML) impairs neutrophil maturation in bone marrow, with mature neutrophils decreasing by over 78% in marrow and 89% in blood. AML-exposed neutrophils acquire inflammatory ...

Also in 2023, ivosidenib was approved for relapsed or refractory myelodysplastic syndromes with IDH1 mutations. Most recently, in 2024, the FDA approved imetelstat for patients with ...

Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Contributed by Tak W. Mak; received May 24, 2022; accepted December 12, 2022; reviewed by Timothy J. Ley and Ravindra Majeti ...